Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access information on a device and to provide personalised ads and content, ad and ...

KeraLink International hosted its first major fundraiser, "Corneatopia: Eyes on the Future," on Nov. 16 at the Maryland ...

Dr. Neda Nikpoor is an ophthalmologist with Jenkins Eye Care. She sits on an advisory board with Project Vision which regularly does screenings in our schools. The Conversation talked with her about ...

You may have heard the term “glaucoma” before, but what is it really, and how do you know if you have it? Glaucoma is an eye disease in which the optic nerve is damaged over time due to elevated ...

In this Healio Video Perspective from Hawaiian Eye 2025, Greg Kunst, CEO of Aurion Biotech, discusses positive phase 1/2 data ...

LONDON - OKYO Pharma Limited (NASDAQ: OKYO), a biopharmaceutical company with a market capitalization of $35.05 million ...

The Company anticipates completing enrollment of the 48-patient trial by the end of 2Q 2025 and releasing top-line data on the Phase 2a trial in 4Q 2025. Results from this trial are anticipated to be ...

Cell therapy company Aurion Biotech is moving forward with plans to IPO despite a pending lawsuit from one of its existing ...

Scheicho Scheifa is haunted by the fear of going blind. A disease called trachoma has turned his eyelids inwards, causing his eyelashes to scar his corneas so badly that one has already turned opaque.

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to ...

Calcitonin gene-related peptide (CGRP) and substance P (SP) had correlations with symptoms and signs of dry eye disease.

The funding will be strategically allocated to support ongoing research and development initiatives, with particular emphasis on fueling progress with OKYO’s lead program, OK-101 focused on treating ...